Drug Profile
Influenza A virus vaccine H5N8 - Seqirus
Alternative Names: Inactivated H5N8 vaccine - Seqirus; Monovalent inactivated influenza A vaccine - SeqirusLatest Information Update: 11 Oct 2022
Price :
$50
*
At a glance
- Originator Seqirus
- Class Influenza A vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza A virus infections
Most Recent Events
- 06 Oct 2022 Influenza A virus H5N8 vaccine is still in phase-I trials for Influenza A virus infections (Prevention) in USA
- 06 Oct 2022 Seqirus plans a phase-II trial in Influenza A virus infections (Prevention) in Q2 2023
- 28 Oct 2019 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(Prevention) in USA (IM, Injection)